Moleculin Biotech Inc (MBRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.02M
Last updated: Nov 17, 2026 at 10:59 AM ET
Moleculin Biotech Inc (MBRX) Earnings: Report Dates and Results
Moleculin Biotech (MBRX) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Moleculin Biotech reported EPS of -$9.59, above the -$9.90 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MBRX has an expected report date of Mar 16, 2027.
MBRX Earnings Call
The latest MBRX earnings call transcript on file is labeled 2025Q1.
Read the 2025Q1 transcriptEarnings History
Of the 38 quarters below that had an estimate, MBRX beat 19, missed 18 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2026, when EPS landed 113.25% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$9.59 | -$9.90 | -$10.80 - -$6.80 | +3.13% | Beat | N/A | 3 | N/A | Nov 13, 2026 |
| Jun 30, 2026 | -$1.40 | -$1.55 | -$1.65 - -$1.45 | +9.68% | Beat | N/A | 3 | 0 up, 0 down | Aug 13, 2026 |
| Mar 31, 2026 | -$3.54 | -$1.66 | -$1.84 - -$1.53 | -113.25% | Miss | N/A | 3 | 0 up, 0 down | May 14, 2026 |
| Dec 31, 2025 | $4.83 | -$122.27 | N/A | +103.95% | Beat | N/A | 3 | 3 up, 0 down | Mar 20, 2026 |
| Sep 30, 2025 | -$0.68 | -$6.58 | -$10.00 - -$4.00 | +89.67% | Beat | N/A | 3 | 3 up, 0 down | Nov 13, 2025 |
| Jun 30, 2025 | -$12.25 | -$10.08 | N/A | -21.53% | Miss | N/A | N/A | 0 up, 0 down | Aug 12, 2025 |
| Mar 31, 2025 | -$17.25 | -$13.87 | N/A | -24.37% | Miss | N/A | N/A | 0 up, 0 down | May 13, 2025 |
| Dec 31, 2024 | -$0.56 | -$1.28 | N/A | +56.60% | Beat | N/A | N/A | 0 up, 0 down | Mar 21, 2025 |
| Sep 30, 2024 | -$71.25 | -$61.00 | -$61.00 - -$61.00 | -16.80% | Miss | N/A | 1 | 0 up, 0 down | Nov 11, 2024 |
| Jun 30, 2024 | -$42.50 | -$62.75 | -$73.00 - -$52.50 | +32.27% | Beat | N/A | 2 | 0 up, 0 down | Aug 13, 2024 |
| Mar 31, 2024 | -$50.50 | -$88.25 | -$89.75 - -$86.75 | +42.78% | Beat | N/A | 2 | 0 up, 0 down | May 10, 2024 |
| Dec 31, 2023 | -$5.02 | -$3.05 | -$3.15 - -$2.85 | -64.59% | Miss | N/A | 3 | 0 up, 0 down | Mar 22, 2024 |
| Sep 30, 2023 | -$71.25 | -$75.00 | N/A | +5.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 13, 2023 |
| Jun 30, 2023 | -$75.94 | -$99.37 | -$108.70 - -$97.45 | +23.58% | Beat | N/A | 3 | 0 up, 0 down | Aug 11, 2023 |
| Mar 31, 2023 | -$103.76 | -$114.37 | N/A | +9.28% | Beat | N/A | 2 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.23 | -$0.30 | -$0.35 - -$0.28 | +23.33% | Beat | N/A | 3 | 0 up, 0 down | Mar 22, 2023 |
| Sep 30, 2022 | -$112.50 | -$103.75 | N/A | -8.43% | Miss | N/A | 2 | 0 up, 0 down | Nov 10, 2022 |
| Jun 30, 2022 | -$96.82 | -$95.62 | N/A | -1.25% | Miss | N/A | 2 | 0 up, 0 down | Aug 15, 2022 |
| Mar 31, 2022 | -$90.00 | -$78.75 | -$82.46 - -$74.96 | -14.29% | Miss | N/A | 2 | 0 up, 0 down | May 11, 2022 |
| Dec 31, 2021 | -$0.09 | -$0.21 | -$0.24 - -$0.18 | +57.14% | Beat | N/A | 3 | 0 up, 0 down | Mar 25, 2022 |
| Sep 30, 2021 | -$79.50 | -$77.50 | -$89.96 - -$59.97 | -2.58% | Miss | N/A | 3 | 1 up, 1 down | Nov 11, 2021 |
| Jun 30, 2021 | -$71.40 | -$70.00 | -$82.46 - -$59.97 | -2.00% | Miss | N/A | 3 | N/A | Aug 12, 2021 |
| Mar 31, 2021 | -$75.00 | -$86.25 | -$112.44 - -$67.47 | +13.04% | Beat | N/A | 3 | N/A | May 12, 2021 |
| Dec 31, 2020 | -$0.26 | -$0.58 | -$0.68 - -$0.51 | +55.17% | Beat | N/A | 3 | N/A | Mar 24, 2021 |
| Sep 30, 2020 | -$224.66 | -$210.00 | -$224.84 - -$202.36 | -6.98% | Miss | N/A | 3 | N/A | Nov 13, 2020 |
| Jun 30, 2020 | -$189.63 | -$202.50 | N/A | +6.36% | Beat | N/A | 3 | N/A | Aug 12, 2020 |
| Mar 31, 2020 | -$227.70 | -$225.00 | N/A | -1.20% | Miss | N/A | 2 | N/A | May 11, 2020 |
| Dec 31, 2019 | -$0.48 | -$0.66 | -$0.78 - -$0.60 | +27.27% | Beat | N/A | 3 | N/A | Mar 19, 2020 |
| Sep 30, 2019 | -$211.05 | -$195.00 | -$202.36 - -$179.87 | -8.23% | Miss | N/A | 2 | N/A | Nov 12, 2019 |
| Jun 30, 2019 | -$192.60 | -$270.00 | N/A | +28.67% | Beat | N/A | 2 | N/A | Aug 16, 2019 |
| Mar 31, 2019 | -$315.00 | -$202.50 | N/A | -55.56% | Miss | N/A | N/A | N/A | May 13, 2019 |
| Dec 31, 2018 | -$225.00 | -$225.00 | N/A | 0.00% | In line | N/A | 2 | N/A | Feb 21, 2019 |
| Sep 30, 2018 | -$180.00 | -$292.50 | N/A | +38.46% | Beat | N/A | N/A | N/A | Nov 13, 2018 |
| Jun 30, 2018 | -$450.00 | -$315.00 | N/A | -42.86% | Miss | N/A | 1 | N/A | Aug 13, 2018 |
| Mar 31, 2018 | -$254.25 | -$315.00 | N/A | +19.29% | Beat | N/A | 1 | N/A | May 15, 2018 |
| Dec 31, 2017 | -$0.96 | -$0.72 | N/A | -33.33% | Miss | N/A | N/A | N/A | Mar 28, 2018 |
| Sep 30, 2017 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 |
| Jun 30, 2017 | -$0.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2017 |
| Mar 31, 2017 | -$0.72 | -$0.66 | N/A | -9.09% | Miss | N/A | N/A | N/A | Apr 3, 2017 |
| Sep 30, 2016 | -$0.12 | -$0.11 | N/A | -9.09% | Miss | N/A | N/A | N/A | Nov 21, 2016 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$25.35, after -$164.81 the year before. It was -$2.21 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$25.35 | N/A |
| Dec 31, 2024 | -$164.81 | N/A |
| Dec 31, 2023 | -$255.97 | N/A |
| Dec 31, 2022 | -$299.55 | N/A |
| Dec 31, 2021 | -$225.99 | N/A |
| Dec 31, 2020 | -$642.25 | N/A |
| Dec 31, 2019 | -$719.13 | N/A |
| Dec 31, 2018 | -$1,109.25 | N/A |
| Dec 31, 2017 | -$2.21 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2025Q1 for the period ended Mar 31, 2025, runs about 3,900 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q1 | Mar 31, 2025 | 3,947 | 7 | |
| 2024Q3 | Sep 30, 2024 | 4,625 | 8 |
2025Q1 Earnings Call
Opening remarks
Jenene Thomas Investor Relations Thank you, Rod, and good morning, everyone. At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Securities Laws and are based on Moleculin’s current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources in the company's own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it does not independently verify and makes no representation as to the adequacy, fairness, accuracy, or completeness or that any independent source has verified any information obtained from third-party sources. Any data discussed regarding clinical trials and progress are considered preliminary and subject to change. Joining us on today's call from Moleculin’s leadership team are Walter Klemp, Chairman and Chief Executive Officer; Dr. John Paul Waymack, Senior Chief Medical Officer; and Jonathan Foster, Executive Vice President and Chief Financial Officer. I’d now like to turn the call over to Walter Klemp. Wally, please proceed.
Walter Klemp Chairman and CEO Thanks, Jenene. Hello, and welcome to our first quarter earnings conference call. For most of our investors, the focus is on the Phase 3 MIRACLE trial, studying Annamycin for the treatment of relapsed and refractory acute Myeloid Leukemia. And with good reason. This trial has now officially started with the first patient already treated and more on the way. In total, we now have 38 sites selected worldwide between the US, Europe, the Middle East, and North Africa. We just announced this week that we also received complete sign off from the European Medicines Agency for all nine countries that we wanted to open in the EU. That was one of the longest lead time items for getting the EU up and running. So it was a major milestone and a real show of support from the EMA for our trial design and our objectives.
Frequently Asked Questions About MBRX
When is Moleculin Biotech's next earnings date?
Moleculin Biotech's next earnings report is expected for Mar 16, 2027.
Did MBRX beat earnings estimates last quarter?
Yes. Moleculin Biotech reported EPS of -$9.59 for the quarter ended Sep 30, 2026, above the -$9.90 estimate, a 3.13% surprise.
What EPS do analysts expect from MBRX next quarter?
The consensus EPS estimate for Moleculin Biotech for the quarter ending Dec 31, 2026 is -$8.70 from 5 analysts, with estimates from -$9.21 to -$8.40.
How often does MBRX beat earnings estimates?
Moleculin Biotech beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +12.98%.
MBRX pages: Overview, Earnings, Forecast, Financials, Competitors